Finally, another study showed that TRAIL-R3 expression on leukemic AML blasts is associated with poor outcome and induces apoptosis-resistance which can be bypassed by targeting TRAIL-R2 with a specific agonistic antibody [289]. The gene discussed is TNFRSF10C; the disease is acute myeloid leukemia.